Third Rock Ventures IV, L.P. - 31 Dec 2025 SCHEDULE 13G/A Report for Maze Therapeutics, Inc. Common Stock, $0.001 par value per share (MAZE)

Filing Manager
Third Rock Ventures IV, L.P.
Reporting Manager
Third Rock Ventures IV, L.P.
Security
Maze Therapeutics, Inc. Common Stock, $0.001 par value per share
Symbol
MAZE
Shares outstanding
48,107,075 shares
Disclosed Ownership
4,473,958 shares
Ownership
9.3%
Form type
SCHEDULE 13G/A
Filing time
13 Feb 2026, 17:25:23 UTC
Date of event
31 Dec 2025
Previous filing
09 May 2025
SEC
View on sec.gov

Reporting Managers (6)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Third Rock Ventures IV, L.P. 9.3% 4,473,958 0 4,473,958 /s/ Kevin Gillis Kevin Gillis, COO of TRV GP IV, LLC, general partner of Third Rock Ventures GP IV, L.P., general partner of Third Rock Ventures IV, L.P.
Third Rock Ventures GP IV, L.P. 9.3% 4,473,958 0 4,473,958 /s/ Kevin Gillis Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC, general partner of Third Rock Ventures GP IV, L.P
TRV GP IV, LLC 9.3% 4,473,958 0 4,473,958 /s/ Kevin Gillis Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC
Third Rock Ventures V, L.P. 2% 950,800 0 950,800 /s/ Kevin Gillis Kevin Gillis, COO of TRV GP V, LLC, general partner of Third Rock Ventures GP V, L.P., general partner of Third Rock Ventures V, L.P.
Third Rock Ventures GP V, L.P. 2% 950,800 0 950,800 /s/ Kevin Gillis Kevin Gillis, Chief Operating Officer of TRV GP V, LLC, general partner of Third Rock Ventures GP V, L.P.
TRV GP V, LLC 2% 950,800 0 950,800 /s/ Kevin Gillis Kevin Gillis, Chief Operating Officer of TRV GP V, LLC